Drug Profile
Research Programme: anti-cancer therapeutics - Cornerstone Pharmaceuticals Inc/National Cancer Institute
Alternative Names: Emulsiphan anti-cancer therapeuticsLatest Information Update: 19 May 2022
Price :
$50
*
At a glance
- Originator Cornerstone Pharmaceuticals; National Cancer Institute (USA)
- Developer Cornerstone Pharmaceuticals Inc; National Cancer Institute (USA)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours